Generation Bio Investor Relations Material
Latest events
Study Result
Generation Bio
Q1 2025
7 May, 2025
Q4 2024
13 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Generation Bio Co
Access all reports
Generation Bio Co. is a biotechnology company focused on the development of genetic medicines to treat both rare and prevalent diseases. Leveraging its proprietary platform, the company is working on a range of therapies aimed at addressing conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GBIO
Country
🇺🇸 United States